Shield Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	41.5	32.18	13.09	5.5	2.06	14.18
Revenue	41.5	32.18	13.09	5.5	2.06	14.18
Revenue Growth (YoY)	93.23%	145.93%	137.95%	167.36%	-85.50%	1389.24%
Cost of Revenue	21.44	17.25	9.06	3.04	1.33	1.85
Gross Profit	20.06	14.93	4.03	2.46	0.73	12.33
Selling, General & Admin	32.84	36.01	37.96	33.65	27.28	11.75
Research & Development	1.88	1.89	1.81	1.32	1.08	3.52
Other Operating Expenses	-0.05	-0.1	-4.41	-0.86	-0.15	-
Operating Expenses	34.67	37.8	35.36	34.1	28.21	15.27
Operating Income	-14.61	-22.87	-31.33	-31.65	-27.48	-2.94
Interest Expense	-6	-3.87	-1.02	-0.4	-	-
Interest & Investment Income	0.23	0.27	0.52	0.04	0.02	0
Currency Exchange Gain (Loss)	-0.08	-0.08	-0.54	0.85	0.52	0.36
Other Non Operating Income (Expenses)	-	-	-0	-0.08	-0.01	-0
EBT Excluding Unusual Items	-20.45	-26.56	-32.38	-31.24	-26.96	-2.57
Asset Writedown	-	-	-	-18.11	-	-
Pretax Income	-20.45	-26.56	-32.38	-49.34	-26.96	-2.57
Income Tax Expense	0.79	0.63	0.92	0.45	-0.31	1.02
Earnings From Continuing Operations	-21.24	-27.18	-33.29	-49.79	-26.65	-3.59
Net Income	-21.24	-27.18	-33.29	-49.79	-26.65	-3.59
Net Income to Common	-21.24	-27.18	-33.29	-49.79	-26.65	-3.59
Shares Outstanding (Basic)	913	783	723	233	204	117
Shares Outstanding (Diluted)	913	783	723	233	204	117
Shares Change (YoY)	19.74%	8.33%	209.85%	14.08%	74.36%	0.21%
EPS (Basic)	-0.02	-0.03	-0.05	-0.21	-0.13	-0.03
EPS (Diluted)	-0.02	-0.03	-0.05	-0.21	-0.13	-0.03
Free Cash Flow	5.05	-6.81	-37.37	-22.66	-25.23	-1.91
Free Cash Flow Per Share	0.01	-0.01	-0.05	-0.10	-0.12	-0.02
Gross Margin	48.34%	46.39%	30.78%	44.70%	35.48%	86.96%
Operating Margin	-35.20%	-71.08%	-239.44%	-575.49%	-1336.01%	-20.74%
Profit Margin	-51.18%	-84.47%	-254.44%	-905.42%	-1295.46%	-25.32%
Free Cash Flow Margin	12.17%	-21.15%	-285.56%	-411.98%	-1226.73%	-13.48%
EBITDA	-14.38	-22.38	-31.08	-29.67	-25.39	0.03
EBITDA Margin	-34.65%	-69.56%	-237.51%	-	-	0.23%
D&A For EBITDA	0.23	0.49	0.25	1.97	2.09	2.97
EBIT	-14.61	-22.87	-31.33	-31.65	-27.48	-2.94
EBIT Margin	-35.20%	-71.08%	-239.44%	-	-	-20.74%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.